PGNY News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PG

Mkt Cap

$2.06B

Volume

814.80K

Next Earnings

November 5th

Loading chart

PG

PGNYProgyny, Inc. Common Stock

PGNY

Pay with—

Available Balance0.00

PG

Mkt Cap

$2.11B

Volume

814.80K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?Progyny (PGNY) shares surged 6.3% following positive insights from its annual selling season, with the company expecting to add 1.2 million new covered lives through the first half of 2027. The fertility benefits provider is projected to report quarterly earnings of $0.51 per share (+13.3% YoY) and revenues of $339.72 million (+8.4% YoY). However, unchanged earnings estimate revisions over the past 30 days suggest the recent rally may lack sustained momentum.Zacks Investment Research · Oct 8, 2026

PGNY or CRL: Which Is the Better Value Stock Right Now?A comparison of two Medical Services stocks reveals that Progyny (PGNY) presents a more attractive value investment opportunity than Charles River Laboratories (CRL). PGNY has a Zacks Rank of #2 (Buy) versus CRL's #3 (Hold), along with superior valuation metrics including a lower forward P/E ratio (12.40 vs 26.89) and a better Value grade (B vs D).Zacks Investment Research · Oct 7, 2026

PGNY vs. CRL: Which Stock Is the Better Value Option?A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.Zacks Investment Research · Sep 18, 2026

Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?Concentra Group (CON) has reached a new 52-week high of $36.05, gaining 82% year-to-date and outperforming its sector. The company maintains a Zacks Rank #1 (Strong Buy) with consistent earnings beat records and a VGM Score of B. However, valuation metrics show the stock trades at a premium to peers (21.7X forward P/E vs. 17X industry average), raising questions about further upside potential.Zacks Investment Research · Sep 15, 2026

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth ConferenceProgyny, Inc. (Nasdaq: PGNY), a women's health and family building solutions company, announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company recently reported record quarterly revenue, gross profit, and adjusted EBITDA for Q2 2026, with strong demand continuing for its women's health and family building solutions.GlobeNewswire Inc. · Aug 7, 2026

What Does the Sale of Progyny Shares by the CFO Mean for Investors?Progyny CFO Mark Livingston sold 8,275 shares (9.47% of his direct holdings) for $211,000 on May 20, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The sale is not considered a red flag as it was non-discretionary. Despite losing a major customer, Progyny's shares rose in Q2 after the company provided strong 2026 guidance projecting 6-9% revenue growth, or 10-13% excluding the lost client's prior contributions.The Motley Fool · Jun 25, 2026

Progyny, Inc. to Present at BofA Securities 2026 Health Care ConferenceProgyny's CEO Pete Anevski and CFO Mark Livingston will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026. The company reported record first quarter 2026 revenue of $328.5 million, reflecting strong demand for women's health and family building solutions.GlobeNewswire Inc. · May 11, 2026

Progyny, Inc. Announces Details for Its First Quarter 2026 Results ReportProgyny, Inc. (Nasdaq: PGNY), a women's health and family building solutions company, announced it will report its Q1 2026 financial results on May 7, 2026, followed by a conference call. The company also announced the launch of the industry's first fully insured supplemental fertility plan for small employers, marking 10 years of operations in redefining women's health and family building care.GlobeNewswire Inc. · Apr 23, 2026

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results ReportProgyny, Inc. announced it will report its financial results for Q4 2025 and full year 2025 on February 26, 2026, after market close. The company will host a conference call at 4:45 p.m. ET to discuss results. A live webcast will be available on the company's investor relations website.GlobeNewswire Inc. · Feb 12, 2026

CEO Peter Anevski Buys $1.9 Million of Progyny Stock: Should Investors Buy Too?Progyny's CEO Peter Anevski purchased 79,500 shares worth approximately $1.9 million, increasing his direct ownership to 680,251 shares. The purchase signals confidence in the company's performance, which has seen 9% sales growth and near-100% customer retention.The Motley Fool · Dec 2, 2025

to start trading

PG

PGNYProgyny, Inc. Common Stock

PGNY

Pay with—

Available Balance0.00

Your PositionYou don't own any PGNY yet.

Related Tickers

Earnings